Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-Year analysis

Andrea Gardini, Giorgio Ercolani, Angela Riccobon, Matteo Ravaioli, Laura Ridolfi, Emanuela Flamini, Ruggero Ridolfi, Gian Luca Grazi, Antonino Cavallari, Dino Amadori

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Objectives: Conventional chemotherapy has not proven effective in improving long-term results of surgery for liver metastases from colorectal cancer. We assessed the usefulness of immunotherapy with tumor infiltrating lymphocytes (TIL) plus Interleukin-2 (IL-2) as adjuvant treatment. Methods: Between 1995 and 1998, 47 patients were enrolled onto a prospective protocol; 25 entered the treatment group (A) and 22 entered the control group (B). All patients had undergone radical liver resection. TIL obtained from surgical specimens from group A patients were cultured and activated in vitro with IL-2, then reinfused into the patients with IL-2. We investigated pre- and post-IL-2 stimulation expression of T cell receptor (TCR) ζ- and ε-chains, p56lck, Fas, and Fas-L by TIL immunostaining. Results: Fourteen patients from group A (56%) received immunotherapy; 14 from group B (60%) underwent conventional chemotherapy, and the remaining 19 patients did not receive any treatment. No significant differences between the two groups were found in the actuarial and disease-free survival (DSF) rates after 1, 3, and 5 years. After IL-2 exposure, TCR ζ-chain expression significantly increased (P = 0.001); An increase in TCR ε-chain expression (P = 0.04), and p56 lck (P = 0.03) was detected; TCR ε-chain expression was significantly increased in disease-free patients compared to those who relapsed (P = 0.04). Fas-L expression was correlated with the TCR ε-chain and p56lck levels (P = 0.05). Conclusions: Our data suggest that we are still a long way from being able to propose TIL + IL-2 treatment as an effective adjuvant therapy. However, the results confirm that the biological indicators examined could play an important role in modulating immunitary response against tumor cells.

Original languageEnglish
Pages (from-to)46-52
Number of pages7
JournalJournal of Surgical Oncology
Volume87
Issue number1
DOIs
Publication statusPublished - Jul 15 2004

Keywords

  • Adoptive immunotherapy
  • Colorectal cancer
  • Liver metastases
  • TIL

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-Year analysis'. Together they form a unique fingerprint.

Cite this